ArticleThe Journal of experimental medicine1996
A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells.
Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
246 citing papers in PubMed, 894 citations in OpenAlex.
- Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.Blood · 2026Article
- Are All Cells Created Equal? Novel Cell-Based Regenerative Therapies in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Review
- Cytokines Associated with Activation of CD4International journal of molecular sciences · 2026Review
- Article
- Control of Asthma and Allergy by Regulatory T Cells.International archives of allergy and immunology · 2025Review
- Heterogeneity and longitudinal transcriptomic characteristics of Tregs in COVID-19 patients.Frontiers in immunology · 2025Article
- Review
- Mechanisms underlying immunosuppression by regulatory cells.Frontiers in immunology · 2024Review
- Recent Advances in Cell-Based In Vitro Models to Recreate Human Intestinal Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Lipid metabolic reprogramming of hepatic CD4Microbiology spectrum · 2023Article
- Exploring Colitis through Dynamic T Cell Adoptive Transfer Models.Inflammatory bowel diseases · 2023Article
- The NQR Complex Regulates the Immunomodulatory Function of Bacteroides thetaiotaomicron.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- The Role of LFA-1 for the Differentiation and Function of Regulatory T Cells-Lessons Learned from Different Transgenic Mouse Models.International journal of molecular sciences · 2023Review
- CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease.International journal of molecular sciences · 2023Review
- The interplay between the microbiota, diet and T regulatory cells in the preservation of the gut barrier in inflammatory bowel disease.Frontiers in microbiology · 2023Review
- Improving the Efficacy of Regulatory T Cell Therapy.Clinical reviews in allergy & immunology · 2022Review
- Transforming growth factor-β1 in regulatory T cell biology.Science immunology · 2022Review
- Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy.Journal of clinical medicine · 2022Review
- Double Negative T Regulatory Cells: An Emerging Paradigm Shift in Reproductive Immune Tolerance?Frontiers in immunology · 2022Review
- Regulatory T cells in autoimmune hepatitis: an updated overview.Journal of autoimmunity · 2021Review
186 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A T helper type 1 (Th1)-mediated colitis with similarities to inflammatory bowel disease in humans developed in severe combined immunodeficiency mice reconstituted with CD45RB(high) CD4+ splenic T cells and could be prevented by cotransfer of CD45RB(low) CD4+ T cells. Inhibition of this Th1 response by the CD45RB(low) T cell population could be reversed in vivo by an anti-transforming growth factor (TGF) beta antibody. Interleukin (IL) 4 was not required for either the differentiation of function of protective cells as CD45RB(low) CD4+ cells from IL-4-deficient mice were fully effective. These results identify a subpopulation of peripheral CD4+ cells and TGF-beta as critical components of the natural immune regulatory mechanism, which prevents the development of pathogenic Th1 responses in the gut, and suggests that this immunoregulatory population is distinct from Th2 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.